犬髓外浆细胞瘤中的 Melan-A 免疫标记

IF 2.3 2区农林科学 Q2 PATHOLOGY

Veterinary Pathology Pub Date : 2024-04-20 DOI:10.1177/03009858241246979

Lukas Schuwerk, Anastasiia Ulianytska, Wolfgang Baumgärtner, Wencke Reineking

{"title":"犬髓外浆细胞瘤中的 Melan-A 免疫标记","authors":"Lukas Schuwerk, Anastasiia Ulianytska, Wolfgang Baumgärtner, Wencke Reineking","doi":"10.1177/03009858241246979","DOIUrl":null,"url":null,"abstract":"Histologic diagnosis of less well-differentiated cases of canine extramedullary plasmacytomas (CEMPs) may require immunohistochemical confirmation to discriminate these tumors from other round cells tumors including lymphoma, cutaneous histiocytoma, and amelanotic melanomas. CEMPs are characterized by widespread immunoreactivity for multiple myeloma 1 (MUM1) antigen and λ light chains, while the melanocytic marker melan-A has been reported to yield negative results. Here, 33 randomly selected CEMPs, 20 melanocytomas, and 20 malignant melanomas were immunohistochemically tested for MUM1, melan-A, and PNL2. In addition, CEMPs were examined for PAX5, E-cadherin, CD3, CD18, CD20, S100, as well as λ and κ light chain immunoreactivity. All CEMPs were characterized by labeling for MUM1 and λ light chain, as well as variable immunopositivity for the remaining antibodies. Notably, 13 cases of CEMPs (39.4%) exhibited immunolabeling for melan-A. Melanocytic tumors immunolabeled for melan-A (40/40; 100%) and PNL2 (34/40; 85%). An unexpected cytoplasmic immunoreactivity for MUM1 was observed in 2 melanocytic tumors. Summarized, MUM1 or melan-A immunomarkers alone are not sufficient to differentiate between CEMPs and amelanotic melanomas and should be part of a larger immunopanel including λ light chain, CD20, and PNL2.","PeriodicalId":23513,"journal":{"name":"Veterinary Pathology","volume":"3 1","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Melan-A immunolabeling in canine extramedullary plasmacytomas\",\"authors\":\"Lukas Schuwerk, Anastasiia Ulianytska, Wolfgang Baumgärtner, Wencke Reineking\",\"doi\":\"10.1177/03009858241246979\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Histologic diagnosis of less well-differentiated cases of canine extramedullary plasmacytomas (CEMPs) may require immunohistochemical confirmation to discriminate these tumors from other round cells tumors including lymphoma, cutaneous histiocytoma, and amelanotic melanomas. CEMPs are characterized by widespread immunoreactivity for multiple myeloma 1 (MUM1) antigen and λ light chains, while the melanocytic marker melan-A has been reported to yield negative results. Here, 33 randomly selected CEMPs, 20 melanocytomas, and 20 malignant melanomas were immunohistochemically tested for MUM1, melan-A, and PNL2. In addition, CEMPs were examined for PAX5, E-cadherin, CD3, CD18, CD20, S100, as well as λ and κ light chain immunoreactivity. All CEMPs were characterized by labeling for MUM1 and λ light chain, as well as variable immunopositivity for the remaining antibodies. Notably, 13 cases of CEMPs (39.4%) exhibited immunolabeling for melan-A. Melanocytic tumors immunolabeled for melan-A (40/40; 100%) and PNL2 (34/40; 85%). An unexpected cytoplasmic immunoreactivity for MUM1 was observed in 2 melanocytic tumors. Summarized, MUM1 or melan-A immunomarkers alone are not sufficient to differentiate between CEMPs and amelanotic melanomas and should be part of a larger immunopanel including λ light chain, CD20, and PNL2.\",\"PeriodicalId\":23513,\"journal\":{\"name\":\"Veterinary Pathology\",\"volume\":\"3 1\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-04-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Veterinary Pathology\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://doi.org/10.1177/03009858241246979\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary Pathology","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1177/03009858241246979","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

犬髓外浆细胞瘤（CEMPs）是一种分化较差的肿瘤，其组织学诊断可能需要免疫组化确认，以便将这些肿瘤与其他圆形细胞瘤（包括淋巴瘤、皮肤组织细胞瘤和黑色素瘤）区分开来。CEMP的特点是对多发性骨髓瘤1（MUM1）抗原和λ轻链具有广泛的免疫反应性，而黑色素细胞标记物melan-A据报道会产生阴性结果。本文随机抽取了33例CEMP、20例黑色素细胞瘤和20例恶性黑色素瘤，对其进行了MUM1、melan-A和PNL2的免疫组化检测。此外，还对 CEMP 进行了 PAX5、E-钙粘蛋白、CD3、CD18、CD20、S100 以及 λ 和 κ 轻链免疫反应的检测。所有 CEMP 的特征都是标记了 MUM1 和 λ 轻链，其余抗体也有不同程度的免疫阳性。值得注意的是，13 例 CEMP（39.4%）表现出黑色素-A 的免疫标记。黑色素细胞肿瘤对黑色素-A（40/40；100%）和PNL2（34/40；85%）免疫标记。在 2 个黑色素细胞肿瘤中意外观察到了 MUM1 的细胞质免疫反应。综上所述，MUM1或melan-A免疫标记物本身不足以区分CEMPs和黑色素瘤，而应作为包括λ轻链、CD20和PNL2在内的更大免疫列表的一部分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Melan-A immunolabeling in canine extramedullary plasmacytomas

Histologic diagnosis of less well-differentiated cases of canine extramedullary plasmacytomas (CEMPs) may require immunohistochemical confirmation to discriminate these tumors from other round cells tumors including lymphoma, cutaneous histiocytoma, and amelanotic melanomas. CEMPs are characterized by widespread immunoreactivity for multiple myeloma 1 (MUM1) antigen and λ light chains, while the melanocytic marker melan-A has been reported to yield negative results. Here, 33 randomly selected CEMPs, 20 melanocytomas, and 20 malignant melanomas were immunohistochemically tested for MUM1, melan-A, and PNL2. In addition, CEMPs were examined for PAX5, E-cadherin, CD3, CD18, CD20, S100, as well as λ and κ light chain immunoreactivity. All CEMPs were characterized by labeling for MUM1 and λ light chain, as well as variable immunopositivity for the remaining antibodies. Notably, 13 cases of CEMPs (39.4%) exhibited immunolabeling for melan-A. Melanocytic tumors immunolabeled for melan-A (40/40; 100%) and PNL2 (34/40; 85%). An unexpected cytoplasmic immunoreactivity for MUM1 was observed in 2 melanocytic tumors. Summarized, MUM1 or melan-A immunomarkers alone are not sufficient to differentiate between CEMPs and amelanotic melanomas and should be part of a larger immunopanel including λ light chain, CD20, and PNL2.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Veterinary Pathology 农林科学-病理学

CiteScore

4.70

自引率

8.30%

发文量

审稿时长

2 months

期刊介绍： Veterinary Pathology (VET) is the premier international publication of basic and applied research involving domestic, laboratory, wildlife, marine and zoo animals, and poultry. Bridging the divide between natural and experimental diseases, the journal details the diagnostic investigations of diseases of animals; reports experimental studies on mechanisms of specific processes; provides unique insights into animal models of human disease; and presents studies on environmental and pharmaceutical hazards.